BMS1

Across TCGA pan-cancer cohorts, BMS1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BMS1 data layer compared with 22 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher BMS1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated BMS1 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where BMS1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.738	0.928	<.001	43	view →
PDAC	OS	Quartile	II,III,IV	0.672	0.971	.002	14	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	11	view →
GBM	OS	Median	All	0.491	0.291	.010	7	view →
HNSC	DFS	Quartile	IV	0.635	0.914	.022	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

BMS1–CCRCC (OS)

Open the CCRCC breakdown →